Asthma Management and the Allergist: Better Outcomes at Lower Cost

The ACAAI handbook, Asthma Management and the Allergist: Better Outcomes at Lower Cost (known as the "Blue Book"), shows that treatment outcomes are better and less expensive when allergists directly provide asthma care or coordinate a care team, compared to when an allergist is not involved. Those outcomes include:

- 76 percent few emergency care visits
- 77 percent fewer hospitalizations and reduced lengths of hospital stays
- 45 percent fewer sick care office visits
- 77 percent fewer missed days from work or school
- Increased patient satisfaction and improved quality of life

References:
The handbook Asthma Management and the Allergist: Better Outcomes at Lower Cost (PDF), sometimes called the "Blue Book.
A PowerPoint presentation of the handbook is available online for veiwing or download.
Image source: Wikipedia, public domain.

Allergic rhinitis increases the risk for future asthma 5-fold

There is strong evidence that there is a relationship between allergic rhinitis (AR) and asthma, but it is unclear whether there is causal. The aim of this study was to assess prospectively whether AR is a risk factor for the diagnosis of asthma.

A historic cohort study had been recorded prospectively since 1967 in four general practices. The study population consisted of 6491 subjects (n = 2081 patients with AR). Average study follow-up was 8.4 years.

In patients with AR, the frequency of newly diagnosed asthma was 7.6% compared to 1.6% in controls (P lower than 0.001). Having AR was a statistically significant risk factor for asthma (hazard ratio: 4.86).

The study authors concluded that a diagnosis of AR was an independent risk factor for asthma. Having physician-diagnosed AR increased the risk almost fivefold for a future asthma diagnosis.

What symptom works best for diagnosis of allergic rhinitis? The answer has been the same for years: eye itching (http://goo.gl/koioJ).

References:

Is physician-diagnosed allergic rhinitis a risk factor for the development of asthma? L. van den Nieuwenhof et al. Allergy, Feb 2010.
Rhinitis is common in asthma and impairs asthma control. Allergy. 2011.
Poor asthma control? – then look up the nose. The importance of co-morbid rhinitis in patients with asthma http://goo.gl/0nNZg
Image source: Wikipedia, Creative Commons license.
Allergic Rhinitis: A Short Review
Mind Maps: Allergic Rhinitis



Treatment Options for Allergic Rhinitis (click to enlarge the image).

Related:

Q&A: If one cetirizine (Zyrtec) pill is good, are two better?

From ACAAI:

Question:

Cosco and Sams having a biding war on cetirizine (where 300 pills cost $10 to $15), you've probably seen patients in your office who are experimenting with dosages on their own. We are used to pushing antihistamines to tolerance with urticaria. Can we extrapolate that to rhinitis? If one 10-mg cetrazine is good, are two or three better for nasal allergy that doesn't seem to respond?

Answer:

Cetirizine studies have clearly identified that there is a dose response problem with sedation. Sedation includes both somnolence and CNS impairment. Even 10 mg/day is associated with sedation greater than placebo. You know there are no reliable data to suggest that 20 or 30 mg/day of cetirizine will provide greater relief of nasal allergies than 10 mg/day.

High-dose antihistamines have their role in chronic urticaria however: High-dose desloratadine (4-times the standard dose) is effective and safe in cold urticaria.

References:
ACAAI News Archive, 02/2010.

"Exciting advance in peanut allergy therapy - oral immunotherapy successful in another study" - CNN

From CNN:

"Researchers took a group of 23 children allergic to peanuts and gave them small amounts of peanuts to eat daily, usually starting with 1 mg. The peanut quantity was increased carefully every two weeks, until the children could eat about five peanuts.

They took this dose daily for at least six weeks, mostly tolerating it well except for some temporary mouth itching or abdominal pain, he said. The results showed that 21 of the 23 children, or 91 percent, can safely eat at least five peanuts every day without any reaction.

"I'm confident that within the next three to five years will we have a treatment that we can offer to our patients, which is not necessarily a cure," Nowak-Wegrzyn told CNN.

The immunotherapy method, which Nowak-Wegrzyn called a "big advancement in the field," has also shown promise in a study by Duke University Medical Center and Arkansas Children's Hospital. Results presented in March 2009 showed that four of nine children allergic to peanuts could be taken off the therapy and eat peanuts freely after 2½ years of the therapy.

But there are many unknowns about this treatment, and it's not clear how permanent the state of desensitization is, she said, and this immunotherapy method is not a cure."

Eight top allergens account for 90 % of all food allergies. They can be remembered by the mnemonic TEMPS WFS:

Tree nuts (almonds, cashews, walnuts)
Egg white (not egg yolk)
Milk
Peanuts
Shellfish (crab, lobster, shrimp)
Wheat
Fish (bass, cod, flounder)
Soy

Food challenges, mind map diagram.

References:
http://www.cnn.com/2010/HEALTH/02/19/aaas.food.allergies/index.html
Blog articles from AllergyNotes
Office-based oral immunotherapy for food allergy is safe and effective - according to Texas allergist group that use it http://goo.gl/S4N8W
Peanut oral immunotherapy (20 peanuts) induces desensitization, however questions about long-term tolerance remain. JACI, 2011.
Eosinophilic esophagitis after specific oral tolerance induction for egg protein http://goo.gl/fzmip
Oral immunotherapy for peanut allergy - interview with Dr. Wesley Burks: clearly 15-20% will not tolerate the treatment http://goo.gl/U45UB
Image source: Roasted peanuts as snack food, Wikipedia, public domain.

Sputum cells from moderate and refractory asthmatics release less IL-6

Mild to moderate asthma is Th2 driven but the cytokines produced in refractory asthma might not fit the classical Th2 pattern.
This study assessed the cytokine production by sputum and blood cells from 15 refractory asthmatics compared to 15 mild untreated and 17 moderate treated asthmatics and 22 healthy subjects:

- interleukin (IL)-4, IL-6, IL-10
- interferon-gamma
- tumor necrosis factor alpha

Moderate and refractory asthmatics were both characterized by a lower production of IL-6 from their airway cells compared to healthy subjects.

The three groups of asthmatics exhibited raised production of IL-4 when compared to healthy subjects. Moderate asthmatics exhibited greater production of IL-10 when compared to refractory asthmatics and healthy subjects.

Sputum cells from moderate and refractory asthmatics release less IL-6.

References:
Manise M, Schleich F, Gusbin N, Godinas L, Henket M, Antoine N, Corhay JL, Louis R. Cytokine production from sputum cells and blood leukocytes in asthmatics according to disease severity. Allergy 2010; DOI: 10.1111/j.1398-9995.2009.02296.x.
Image source: Interleukin 6. Wikipedia, PDB rendering based on 1ALU, public domain.

Video: How the immune system works

Not what you expected from the title, but you will not be disappointed to see this 30-second video... :)

Related: A competitor emerges from the freezing water during the 2011 Tough Guy Challenge January 30, 2011 in Perton, England. (Michael Regan/Getty Images). Winter sports beat winter blues - The Big Picture - Boston.com.

New FDA safety requirements for Long-Acting Beta-Agonists (LABAs): never take LABAs alone, use only for shortest time

Update from Thorax 2012: Clearing the air: LABA/ICS reduce asthma hospitalizations, not associated with life-threatening events and deaths http://goo.gl/TesRp

- The use of LABAs is contraindicated without the use of an asthma controller medication such as an inhaled corticosteroid. Single-ingredient LABAs should only be used in combination with an asthma controller medication; they should not be used alone. LABAs must never be taken alone for the treatment of asthma. Long-Acting Beta Agonists (LABAs) should not be started in patients with acutely deteriorating asthma.

Currently, LABAs are approved as single-ingredient products (Serevent and Foradil) and as an ingredient in combination products containing inhaled corticosteroids (Advair and Symbicort) for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

- LABAs should only be used long-term in patients whose asthma cannot be adequately controlled on asthma controller medications.

- LABAs should be used for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is achieved.

- Pediatric and adolescent patients who require the addition of a LABA to an inhaled corticosteroid should use a combination product containing both an inhaled corticosteroid and a LABA, to ensure compliance with both medications.


Advair Diskus (left), Symbicort Turbuhaler (right). Image sources: Wikipedia, public domain.

The LABAs labels must state that:

- asthma patients must not take LABAs on a long-term basis unless their condition cannot be adequately controlled with other medications such as inhaled corticosteroids.

- the LABAs should never be used alone in the treatment of asthma in adults or children.

95% of asthma patients using an LABA receive it in combination with a corticosteroid in a single inhaled product such as Advair Diskus, Advair HFA, or Symbicort.

"We think the greater public health benefit is to reduce the use of LABAs, but keep them available for patients who really need them," said John Jenkins, MD, director of the Office of New Drugs in the FDA's Center for Drug Evaluation and Research during the news conference. "There is still a benefit to these drugs for patients who aren't absolutely controlled on asthma-control medications."

Specific Label Changes for Long-Acting Beta-Agonists (LABAs)

1. Contraindicate the use of LABAs for asthma in patients of all ages without concomitant use of an asthma-controller medication such as an inhaled corticosteroid.

2. Stop use of the LABA, if possible, once asthma control is achieved and maintain the use of an asthma-controller medication, such as an inhaled corticosteroid.

3. Recommend against LABA use in patients whose asthma is adequately controlled with a low- or medium-dose inhaled corticosteroid.

4. Recommend that a fixed-dose combination product containing a LABA and an inhaled corticosteroid be used to ensure compliance with concomitant therapy in pediatric and adolescent patients who require the addition of a LABA to an inhaled corticosteroid.

The risk of serious asthma exacerbations and asthma-related death is not unique to LABAs. It has been known for over 50 years that SABAs can worsen asthma and cause asthma-related death. The FDA will require manufacturers of LABAs to conduct large clinical trials that evaluate this risk by comparing inhaled corticosteroids plus LABAs with inhaled corticosteroids alone.

Related:

The Science Business Blog - Forbes.com, 2010.
Risk of asthma exacerbations: Relative to SABA-only therapy, LABA use is associated with a lower risk of ED visit http://goo.gl/4sDc9

Anti-inflammatory action of insulin targets the innate immunity via protease-activated receptor 2 (PAR-2)

Anti-inflammatory effects of insulin may share a signaling pathway with the protease-activated receptor 2 (PAR-2), a G protein-coupled receptor.

Insulin reduced PAR(2)-induced inflammation in a murine model, attenuated PAR(2)-induced leukocyte trafficking, and reduced PAR(2) calcium signaling.

This effect of insulin to attenuate PAR(2)-mediated inflammation was reversed when cells were preincubated with a pan-protein kinase C inhibitor).

The enhanced inflammatory effect of PAR(2) was attenuated by the local administration of insulin at the inflammatory site.

Anti-inflammatory action of insulin targets the acute innate inflammatory response triggered by PAR(2).


Effect of insulin on glucose uptake and metabolism. Insulin binds to its receptor (1) which in turn starts many protein activation cascades (2). These include: translocation of Glut-4 transporter to the plasma membrane and influx of glucose (3), glycogen synthesis (4), glycolysis (5) and fatty acid synthesis (6). Image source: Wikipedia, public domain.

References:
Insulin Modulates Protease-Activated Receptor 2 Signaling: Implications for the Innate Immune Response. Hyun E, Ramachandran R, Cenac N, Houle S, Rousset P, Saxena A, Liblau RS, Hollenberg MD, Vergnolle N. J Immunol. 2010 Jan 29. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20118282?dopt=Abstract

Chromosome 11q13.5 variant associated with atopic dermatitis - in addition to filaggrin (FLG) mutations

Atopic eczema is a common inflammatory skin disease with multifactorial etiology. The genetic basis is incompletely understood; however, loss of function mutations in the filaggrin gene (FLG) are the most significant and widely replicated genetic risk factor.

The first genome-wide association study in atopic eczema recently identified 2 novel genetic variants in association with eczema susceptibility:

- a single nucleotide polymorphism (SNP) on chromosome 11q13.5

- a single nucleotide polymorphism (SNP) within the gene encoding hornerin on chromosome 1q21

The 4 most common FLG null variants were strongly associated with atopic eczema.

The 11q13.5 (rs7927894) association was independent of the well-established FLG risk alleles and may be multiplicative in its effect.

There was no association between 1q21/rs877776 and pediatric eczema in this study.

References:
Chromosome 11q13.5 variant associated with childhood eczema: An effect supplementary to filaggrin mutations. O'Regan GM, Campbell LE, Cordell HJ, Irvine AD, McLean WH, Brown SJ. J Allergy Clin Immunol. 2010 Jan;125(1):170-174.e2.
http://www.ncbi.nlm.nih.gov/pubmed/20109745?dopt=Abstract
Image source: Chromosome 11 Chart. Wikipedia, public domain.

Defect of regulatory T cells in Omenn syndrome leads to a breakdown of peripheral tolerance and autoimmune complications

Omenn syndrome (OS) is an autosomal-recessive disorder characterized by severe immunodeficiency (SCID) and T-cell-mediated autoimmunity. Omenn syndrome is due to RAG enzyme defects.


Severe Combined Immunodeficiency (SCID) (click to enlarge the image).

The Omenn syndrome is caused by hypomorphic mutations in recombination-activating genes that hamper the process of Variable (V) Diversity (D) Joining (J) recombination (recombinase genes RAG-1 and RAG-2), leading to the generation of autoreactive T cells.

Receptor editing reactivates RAG-1 and RAG-2 when a high affinity self-antigen is recognized by a B cell receptor (BCR).

The expression of autoimmune regulator, a key factor governing central tolerance, is markedly reduced.

The researchers analyzed forkhead box protein P3 (FOXP3) expression in peripheral blood T cells and lymphoid organs in OS. They also tested the suppressive activity of CD4(+) CD25(high) peripheral blood T cells (T regs).

CD4(+)CD25(high)T cells (T regs) failed to suppress proliferation of D4(+) responder T cells. Immunohistochemical analysis of FOXP3 expression in lymph nodes and thymus showed a severe reduction of this cell subset.

A defect of regulatory T cells in OS leads to a breakdown of peripheral tolerance, which then leads to autoimmune complications.

Regulatory T cells - 5 groups have been described as of year 2010:

- CD4+CD25+ regulatory T cells ("classic" T regs)
- TR1 cells, CD4 cells that secrete IL-10
- Th3 cells, a subset of CD4+ cells that secrete TGF-b
- CD8+ suppressor T cells
- γ/δ T cells


Regulatory T cells - 5 groups have been described as of year 2010 (click to enlarge the image).


Severe combined immunodeficiency (SCID) - 4 groups according to T/B/NK cells (click to enlarge the image).

In SCID, the younger the age of the patient at the time of transplantation, the better the prognosis. There is a 95% survival rate in an infant who undergoes a transplant before 3 months of age. After six months, the survival rate decreases dramatically, to 50%.

Conditions with elevated IgE

Atopic dermatitis, Asthma, ABPA, and allergic fungal sinusitis
Infections (parasites, HIV, TB, EBV, and CMV)
Malignancy (IgE myeloma and lymphoma)
Churg-Strauss syndrome
Kimura’s disease, painless, unilateral cervical lymphadenopathy or subcutaneous masses in the head or neck region

Immunodeficiency diseases with elevated IgE

Hyper IgE syndrome (HIES)
Wiskott-Aldrich syndrome (WAS)
Omenn syndrome
DiGeorge syndrome (DGS)
Netherton syndrome, form of ichthyosis associated with SPINK5
Nezelof syndrome, congenital hypoplasia of the thymus with retention of normal parathyroid function (in contrast to complete DiGeorge syndrome in which there is absence of the parathyroids)

References:
Defect of regulatory T cells in patients with Omenn syndrome. Cassani B, Poliani PL, Moratto D, Sobacchi C, Marrella V, Imperatori L, Vairo D, Plebani A, Giliani S, Vezzoni P, Facchetti F, Porta F, Notarangelo LD, Villa A, Badolato R. J Allergy Clin Immunol. 2010 Jan;125(1):209-216.
http://www.ncbi.nlm.nih.gov/pubmed/20109747?dopt=Abstract
Mind Maps: Primary Immunodeficiency Disorders (PIDD)

Is asthma prevalence increasing or decreasing?

There are large variations globally in the prevalence of asthma in children.

Time trends have shown a mixed picture:

- increases in low prevalence centres
- plateau or even a decrease in high prevalence centres

Atopy has less influence on asthma in low and middle income countries. Breast feeding exerts a protective effect only on non-atopic asthma in non-affluent countries.

References:
Recent perspectives on global epidemiology of asthma in childhood. Asher MI. Allergol Immunopathol (Madr). 2010 Jan 25. [Epub ahead of print]
Image source: Openclipart.org, public domain.

Anti-inflammatory action of theophylline in asthma may be mediated through reduction of dendritic cells

Theophylline has an anti-inflammatory action that may be mediated in part through reduction of inflammatory cells in the airways.

Dendritic cells (DCs) are professional antigen-presenting cells, capable of priming naïve T cells, and play key roles in the activation of immune responses in asthma.


Dendritic cells are the key antigen presenting cells of the immune system. This video describes how they do this. This video is from: Janeway's Immunobiology, 7th Edition.

Peripheral human blood monocytes were incubated with:
- theophylline
- KF17837 (a selective A2a receptor antagonist)
- enprofylline (A2b receptor antagonist)
- and co-incubated with selective adenosine A1 and A2a receptor agonists to determine their effects on DC differentiation

The number of DCs was remarkably reduced by 60-70% by theophylline. This effect was reversed by the addition of A1 agonists or A2a agonist.

These findings suggest that the adenosine A1 and A2a receptors contribute to DC differentiation and survival.

References:
Theophylline inhibits the differentiation of human monocyte into dendritic cell potentially via adenosine receptor antagonism. Yasui K, Kondo Y, Wada T, Yashiro M, Tsuge M, Morishima T. Clin Exp Allergy. 2009 Dec;39(12):1857-65
Low-dose theophylline improved asthma control more than montelukast - a safe and low-cost LTRA alternative? http://goo.gl/wBn4D
Roflumilast decreases allergen-induced inflammation in mild asthma - this is is similar to other PDE4 inhibitors http://goo.gl/Yi740

Video: Gluten-free Cooking

Gluten-free Cooking from ChefMD.
Related: Nonceliac gluten-sensitive enteropathy (NCGSE) common in allergic patients - biopsy part of the routine investigation? http://goo.gl/gwdT3

Immunotherapy Against Allergic Rhinitis - State of the Art 2010 Review

Allergic rhinitis is the most prevalent type I allergy in industrialized countries. Pollen scattering from trees or grasses often induces seasonal allergic rhinitis, which is also known as pollinosis or hay fever.

Impaired performance due to pollinosis and/or medication used for treating pollinosis is considered to be an important reason for the loss of concentration and productivity in the workplace.

Antigen-specific immunotherapy is an only available curative treatment against allergic rhinitis. Subcutaneous injection of allergens (SCIT) with or without adjuvant has been commonly used as an immunotherapy. Recently, sublingual administration (SLIT) has come to be considered a safe and convenient alternative administration route of allergens.

The biomarkers and therapeutic mechanisms for immunotherapy are not fully understood. Tr1 and regulatory T cells are likely involved in the therapeutic mechanisms underlying SCIT and SLIT.

This review also focuses on the current immunotherapeutic approach to treating Japanese cedar pollinosis, the most prevalent pollinosis in Japan, including:

- sublingual immunotherapy with standardized extract
- a transgenic rice-based edible vaccine
- an immunoregulatory liposome encapsulating recombinant fusion protein

References:
Antigen-Specific Immunotherapy against Allergic Rhinitis: The State of the Art. Fujimura T, Okamoto Y. Allergol Int. 2010 Feb 25;59(1). [Epub ahead of print]
How to Write a Subcutaneous Immunotherapy (SCIT) Prescription for Allergic Rhinitis
Anaphylactic Reaction to Subcutaneous Immunotherapy in a Patient with Asthma: How Do You Change the Dose?
Image source: OpenClipArt.org, public domain.



Treatment Options for Allergic Rhinitis (click to enlarge the image).

Nut allergy decreases quality of life of both children and parents, epinephrine auto-injector reduces anxiety

Nut allergy is known to impact on the quality of life (QoL) and anxiety of both the allergic child and their parents.

41 nut allergic children (age 6-16 yrs) and their mothers completed questionnaires to assess maternal and children's QoL, anxiety and stress.

Children with nut allergy had poorer emotional, social, and psychological QoL compared to healthy normative data. This was not influenced by the severity of previous reactions.

Mother and child reported lower anxiety when the child was prescribed an epinephrine auto-injector.

Prescribing auto-injectors was associated with reduced anxiety for food allergic children and their mothers, but was not associated with reduced risk-taking behavior.

My opinion: EpiPen is not cheap and with the possibility of a bi-phasic reaction (a second reaction at a later time), most people will need 2 injectors, just in case. However, an epinephrine injector can literally make the difference between life and death in an anaphylactic reaction. If EpiPen (or any other epinephrine injector) is recommended by your doctor, you should carry it with you at all times.

References:
Management of nut allergy influences quality of life and anxiety in children and their mothers.
Cummings AJ, Knibb RC, Erlewyn-Lajeunesse M, King RM, Roberts G, Lucas JS. Pediatr Allergy Immunol. 2010 Jan 14.
Individuals with allergic rhinitis appear to be at a higher risk for developing anxiety and mood disorders - study http://goo.gl/hIwq9

Why Do So Many Athletes, and Winter Olympians Especially, Have Asthma?

The prevalence of exercise-induced bronchoconstriction (EIB) is 10% in the general population, up to 90% of those with asthma, and 50% of those with allergic rhinitis.

From the NYTimes:

Most experts think that the problem is not with the coldness of the air but with the "dryness."

Exercise-induced asthma has been diagnosed in as many 50% of all elite cross-country skiers and almost as many world-class ice skaters and hockey players. It’s far more common in winter athletes than in those who compete in the summer, although 17% of Olympic-level distance runners have been given the same diagnosis.

Exercise-induced asthma is not quite the same condition as asthma. The “preferred term” for exercise-induced asthma is exercise-induced bronchoconstriction, or E.I.B. “It’s a reversible, obstructive airway disease” that typically begins about 5 minutes after you stop exercising — particularly if your exercise was intense, “at 85 -95% of maximum heart rate,” Dr. Randolph says.

Exercise-induced bronchospasm (EIB) (click to enlarge the image):



About 90% of people with asthma also suffer from E.I.B. But people can also suffer from E.I.B. without underlying asthma.

Lungs need water-saturated air. If the air entering your bronchial tubes is dry, as it usually is in winter, the cells lining your airway release their own moisture to humidify it.

“Think of a sponge being squeezed,” Dr. Randolph says. The squeezing and loss of moisture prompt certain cells within the bronchial tube to release allergic chemicals that initiate an inflammatory process, slowly closing your throat. Thankfully, the process is “self-limiting,” Dr. Randolph says. “No one dies” of exercise-induced bronchoconstriction. (Although some athletes have died from uncontrolled asthma attacks, a different issue.)

Those study subjects who perspired, spit and cried the least were also the most prone to exercise-induced asthma. However, drinking more water hasn’t been shown to combat E.I.B.

ATS practice guideline: exercise-induced bronchoconstriction:



References:

Why Do So Many Winter Olympians Have Asthma? NYT, 2010.

Exercise-induced asthma and bronchospasm

49-year-old man with childhood asthma who was told he would never be able to do exercise runs a marathon every day for a year. CNN, 2011.

Asthma remains the most common health problem among elite athletes. "Regular, moderate exercise can improve your immune system, which can also help avoid asthma attacks". BMJ, 2012.

An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2013 May 1;187(9):1016-27. doi: 10.1164/rccm.201303-0437ST.
http://www.ncbi.nlm.nih.gov/pubmed/23634861

IgE against Ara h2 can distinguish between peanut sensitization and peanut allergy

From MedPage Today:

"Standard tests" showed that 10% of eight-year-olds in a British cohort were sensitive to peanuts but only one in 50 was actually allergic when the children were challenged with the legumes.

Standard methods were defined as a skin prick test producing a wheal whose diameter was at least three millimeters greater than a negative control, and/or a IgE response of at least 0.2 kiloUnits of peanut allergen per liter of serum.

The serum immunoglobulin E (IgE ) response to a single peanut protein, dubbed Ara h 2, was able to distinguish between the sensitivity and allergy in most cases.

Avoiding peanuts only makes sense if child is really allergic.

Currently, a double-blind, placebo-controlled food challenge (DBPCFC) is the gold standard for diagnosing peanut allergy, but it's time-consuming, costly, and risks a severe reaction.

The diagnostic value of specific IgE to Ara h 2: the need for peanut challenges could be reduced by at least 50% http://buff.ly/UueEhx

References:

Test Improves Peanut Allergy Diagnosis. MedPage Today, 2010.
Peanut allergy: Patients with a positive SPT greater than the 95% PPV do not need an Arah2 testing undertaken http://bit.ly/SwbwBQ
Peanut allergy: Diagnostic accuracy of sIgE to Ara h 6 in adults is as good as Ara h 2 http://buff.ly/1uU314i
Image source: Degranulation processes. Wikipedia, GNU Free Documentation License.

Pregnant women who consumed a lot of green and yellow vegetables, and citrus fruit had a lower risk of eczema in their babies

Two previous studies showed inverse relationships between maternal vitamin E and zinc intake during pregnancy and the risk of wheeze and/or asthma in the offspring.

This study included 763 Japanese mother and their children, and investigated the association between maternal intake of vegetables, fruit, and selected antioxidants during pregnancy and the risk of wheeze and eczema in the offspring aged 16–24 months.

Higher maternal intake of green and yellow vegetables, citrus fruit, and β-carotene during pregnancy was associated with a reduced risk of eczema, but not wheeze.

Maternal vitamin E consumption during pregnancy was inversely related to the risk of infantile wheeze, but not eczema.

No associations were observed between maternal intake of total vegetables, vegetables other than green and yellow vegetables, total fruit, apples, α-carotene, vitamin C, or zinc and the risk of wheeze or eczema in the children.

The authors concluded that higher maternal consumption of green and yellow vegetables, citrus fruit, and β-carotene during pregnancy may be protective against the development of eczema in the offspring. On the other hand, higher maternal vitamin E intake during pregnancy may reduce the risk of infantile wheeze.

Diet for the prevention of asthma and allergies in early childhood: there are no evidence-based recommendations (http://goo.gl/j3Al8).

References:

Consumption of vegetables, fruit, and antioxidants during pregnancy and wheeze and eczema in infants. Y. Miyake 1 , S. Sasaki 2 , K. Tanaka 1 & Y. Hirota 3. Allergy, Jan 2010.
Maternal diet during lactation and allergic sensitization in the offspring at age of 5 - Finnish study, 2011. http://goo.gl/wHMgF
Image source: Wikipedia, public domain.

Allergy and Immunology News of the Day

Health News of the Day is a daily summary made from the selected links I post on Twitter. It is in bullet-point format with links to the original sources which include 350 RSS feeds that produce about 2,500 items per day.

Food allergies in children, including peanut allergy, have increased by nearly 20% in the last 10 years http://bit.ly/3AjDHQ

RT @MatthewBowdish Controversy surrounding genetically-engineered 'hypo-allergenic' cats http://bit.ly/jHV0n

Hypersensitivity reactions to mAbs: experience with rapid desensitization to rituximab, infliximab, and trastuzumab http://bit.ly/30b1xd

Psychological distress from food allergy: Maternal reports of child symptoms were higher than child self-reports http://bit.ly/1HD5ff

Familial atypical cold urticaria: Description of a new hereditary disease. http://bit.ly/77gtV

Add-on omalizumab is effective and well tolerated in children (6-12 years) with allergic asthma not controlled with ICS http://bit.ly/1NnyJR

Hypereosinophilic syndrome: A multicenter analysis of clinical characteristics and response to therapy http://bit.ly/1B9qgd

High parental education protects children from non-atopic wheeze due to lower smoking and higher breastfeeding rates http://bit.ly/3GprQJ

Recognize 'discords' of 'immune-system symphonic orchestra', brighten up dark and winding road of immunodeficiencies http://bit.ly/OqOTy       

Medical news tweets are not research articles - they are 140-character messages - please always go to the original source, links, etc. Tweets and links do not represent endorsement, approval or support. Image source: OpenClipArt.org, public domain.

Follow me on Twitter:

Modification of home environment had no effect on development of respiratory symptoms in infants

Previous studies have suggested that environmental exposures may be related to the development of respiratory symptoms in early life. Intervention studies, however, have not produced consistent findings.

The Peer Education in Pregnancy Study examined the effect of home environment intervention with pregnant women at risk for having children with asthma on the development of respiratory symptoms in their infants.

383 pregnant women whose unborn child had a first-degree relative with an allergic history were randomized to 1 of 2 intervention groups.

The intensive education group received 3 home visits focused on home environment modification.

Families in both intervention groups showed significant changes in several environmental factors:

- insects other than cockroaches
- use of mattress covers
- washing in hot water

Children in the intensive education group did not have statistically significant decrease in respiratory symptoms.

The results of this study do not provide support for a primary intervention focused on general modification of the home environment during pregnancy for high-risk children.


Mind map: Indoor allergens. See more Allergy and Immunology mind maps at AllergyCases.org.

Where are highest concentrations of dust mites found in home? Pillows, stuffed animals, mattress, bedding? http://goo.gl/l6KtR -- A: Mattress.

References:

The effect of low-cost modification of the home environment on the development of respiratory symptoms in the first year of life. Persky V, Piorkowski J, Hernandez E, Chavez N, Wagner-Cassanova C, Freels S, Vergara C, Pelzel D, Hayes R, Gutierrez S, Busso A, Coover L, Thorne PS, Ownby D. Ann Allergy Asthma Immunol. 2009 Dec;103(6):480-7.

How can I build an allergen-free home? AAAAI Ask the Expert has some tips: http://goo.gl/dMT91

Image sources: Heap of pancakes in Sweden; Yellow mite, Wikipedia, public domain.